Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumoursStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 August 2025
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)Product type:GuidanceProgramme:HealthTech guidancePublished: 16 May 2024
Irreversible electroporation for primary liver cancer (HTG532)Product type:GuidanceProgramme:HealthTech guidancePublished: 27 November 2019
Irreversible electroporation for treating liver metastases (HTG304)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 February 2013
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2018
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Living-donor liver transplantation (HTG390)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 November 2015
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (HTG575)Product type:GuidanceProgramme:HealthTech guidancePublished: 21 April 2021
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liverStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 15 October 2026
Microwave ablation for treating liver metastases (HTG409)Product type:GuidanceProgramme:HealthTech guidancePublished: 27 April 2016
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 November 2026
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 October 2026
Percutaneous Laser (Photo) Ablation of Liver TumoursStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Radiofrequency ablation of hepatocellular carcinoma (HTG1)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 July 2003
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 July 2024Published: 31 March 2021
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (HTG720)Product type:GuidanceProgramme:HealthTech guidancePublished: 16 May 2024
Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 July 2013
Selective internal radiation therapy for unresectable colorectal metastases in the liver (HTG542)Product type:GuidanceProgramme:HealthTech guidancePublished: 4 March 2020
Selective internal radiation therapy for unresectable colorectal metastases in the liverStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (HTG489)Product type:GuidanceProgramme:HealthTech guidancePublished: 31 October 2018
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)Product type:GuidanceProgramme:HealthTech guidancePublished: 29 August 2012
Sorafenib for treating advanced hepatocellular carcinoma (TA474)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 15 April 2026
Technologies for the detection of Hepatocellular CarcinomaStatus:Awaiting developmentProgramme:HealthTech guidanceExpected publication date: TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Transarterial Chemoembolisation for inoperable hepatocellular carcinomaStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Transarterial radio embolisation for osteosarcoma liver metastasesStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC